默沙东PD-1抑制剂可瑞达（帕博利珠单抗注射液）在华获批原发晚期或复发性子宫内膜癌适应症

Core Viewpoint - Merck's PD-1 inhibitor, Pembrolizumab (brand name: Keytruda), has received approval from the National Medical Products Administration (NMPA) in China for use in combination with Carboplatin and Paclitaxel as a first-line treatment for adult patients with mismatch repair-deficient (dMMR) advanced or recurrent endometrial cancer, followed by Pembrolizumab monotherapy for maintenance treatment. This approval is based on data from the Phase III clinical trial KEYNOTE-868 (NRG-GY018) [2]. Group 1 - Merck's Pembrolizumab has been approved for a new indication in China [2] - The approval is for use in combination with Carboplatin and Paclitaxel [2] - The indication is specifically for dMMR advanced or recurrent endometrial cancer [2] Group 2 - The approval follows data from the Phase III clinical trial KEYNOTE-868 [2] - The treatment includes a maintenance phase with Pembrolizumab monotherapy [2]